Two cell lines, acute myeloid eosinophilic leukaemia (EOL-1) and malignant rhabdoid tumour (A-204), sensitive to BRD9 inhibition/degradation and dependent on an active BAF complex, were selected to study the impact of degrader-induced BRD7/9 degradation on the viability of cancer cells. The gene discussed is BRD9; the disease is cancer.